Advanced Viral Research Corp. (ADVR.OB) is a biopharmaceutical company focused on improving the lives of patients by researching, developing and marketing innovative therapies for a range of serious disorders and diseases.
The company is primarily committed to bringing its flagship product, AVR118, to patients. AVR118 appears to have the potential to stimulate the pro-inflammatory response needed to fight viral infections, including HIV, as well as reduce aberrant autoimmune-type inflammatory responses.
In January of 2005, Advanced Viral Research Corp. reported the results from its Phase I/II clinical trial of AVR118 in patients with AIDS. The results demonstrated that the product has continued to show potential to offer unique benefits, a favorable safety profile, and no apparent drug-related undesirable effects.
Let us hear your thoughts: Advanced Viral Research Corp. Message Board